ADMA Adma Biologics Inc
Price (delayed)
$16.26
Market cap
$3.79B
P/E Ratio
108.4
Dividend/share
N/A
EPS
$0.15
Enterprise value
$3.83B
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at
Highlights
The company's net income has surged by 186% YoY
The EPS has surged by 175% year-on-year
Key stats
What are the main financial stats of ADMA
Market
Valuations
Earnings
Shares outstanding
233.08M
Market cap
$3.79B
Enterprise value
$3.83B
Price to earnings (P/E)
108.4
Price to book (P/B)
20.02
Price to sales (P/S)
11.44
EV/EBIT
64.61
EV/EBITDA
56.63
EV/Sales
11.61
Revenue
$330.24M
EBIT
$59.34M
EBITDA
$67.7M
Free cash flow
$66.64M
Per share
Balance sheet
Liquidity
EPS
$0.15
Free cash flow per share
$0.29
Book value per share
$0.81
Revenue per share
$1.42
TBVPS
$1.6
Total assets
$376.4M
Total liabilities
$188.13M
Debt
$132.22M
Equity
$188.27M
Working capital
$259.51M
Debt to equity
0.7
Current ratio
6.87
Quick ratio
2.68
Net debt/EBITDA
0.65
Margins
Efficiency
Dividend
EBITDA margin
20.5%
Gross margin
46.1%
Net margin
10.5%
Operating margin
25.4%
Return on assets
9.9%
Return on equity
22.1%
Return on invested capital
16%
Return on capital employed
17.9%
Return on sales
18%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ADMA stock price
How has the Adma Biologics stock price performed over time
Intraday
-2.87%
1 week
-6.07%
1 month
37.1%
1 year
306.5%
YTD
259.73%
QTD
45.44%
Financial performance
How have Adma Biologics's revenue and profit performed over time
Revenue
$330.24M
Gross profit
$152.3M
Operating income
$83.94M
Net income
$34.79M
Gross margin
46.1%
Net margin
10.5%
The company's net income has surged by 186% YoY
The gross profit has soared by 167% YoY and by 37% from the previous quarter
The company's net margin has surged by 154% YoY
Adma Biologics's operating income has surged by 90% QoQ
Growth
What is Adma Biologics's growth rate over time
Valuation
What is Adma Biologics stock price valuation
P/E
108.4
P/B
20.02
P/S
11.44
EV/EBIT
64.61
EV/EBITDA
56.63
EV/Sales
11.61
The EPS has surged by 175% year-on-year
The price to book (P/B) is 120% higher than the last 4 quarters average of 9.1
The equity has increased by 28% year-on-year and by 22% since the previous quarter
ADMA's price to sales (P/S) is 133% higher than its 5-year quarterly average of 4.9 and 124% higher than its last 4 quarters average of 5.1
ADMA's revenue has surged by 59% year-on-year and by 17% since the previous quarter
Efficiency
How efficient is Adma Biologics business performance
The company's return on assets has surged by 182% YoY
ADMA's ROE has soared by 175% YoY
The return on sales has surged by 161% since the previous quarter
Dividends
What is ADMA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ADMA.
Financial health
How did Adma Biologics financials performed over time
Adma Biologics's total assets is 100% more than its total liabilities
ADMA's quick ratio is up by 50% QoQ and by 13% YoY
ADMA's current ratio is up by 32% QoQ and by 8% YoY
The company's debt is 30% lower than its equity
The equity has increased by 28% year-on-year and by 22% since the previous quarter
Adma Biologics's debt to equity has decreased by 27% YoY and by 19% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.